Roche and IBM to Co-Develop, Commercialize IBM's DNA Transistor Technology for Nanopore Sequencing

Roche will fund development of the nanopore sequencer at IBM, and will receive an exclusive right to market products based on the technology. A device could be brought to market in five years, according to a Roche executive.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.